Stanislava Yordanova

Dr. Stanislava Yordanova

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
YAYuliana Asenova Atanasova
Yuliana Asenova Atanasova
AUAnastasia Ushtanit
Anastasia Ushtanit
SYStanislava Yordanova
Stanislava Yordanova
ABAna Baykova
Ana Baykova
EBElizabeta Bachiyska
Elizabeta Bachiyska
We investigated the rise of nontuberculous mycobacteria (NTM) infections in Bulgaria, focusing on species identification and distribution from 2018 to 2022. Utilizing advanced diagnostic tools, including the Hain Mycobacterium CM/AS method, Myco-biochip assay, and whole-genome sequencing, the study identifies and characterizes a diverse range of Mycobacterium species from clinical samples. While M. avium, M. gordonae, M. fortuitum, and M. chelonae were dominating, a number of rare species were also found. They include such species as M. marseillense and M. celatum. Moreover, the noticeable prevalence of M. terrae complex species missed by conventional testing was observed. We identified a rare species, highly homologous to previously described strains from Japan; based on genome–genome distance data, we propose its reannotation as a new species. Further, a novel species was identified, which is significantly distinct from its closest neighbor, M. iranicum, with ANI = 87.18%. Based on the SeqCode procedure, we propose to name this new species Mycobacterium bulgaricum sp. nov. Dynamic changes in NTM species prevalence in Bulgaria observed from 2011 to 2022 highlight the emergence of new species and variations tied to environmental and demographic factors. This underscores the importance of accurate species identification and genotyping for understanding NTM epidemiology, informing public health strategies, and enhancing diagnostic accuracy and treatment protocols.

31 August 2022 in Folia Medica
Verified
Journal Article
Open access
PDF file
SYStanislava Yordanova
Stanislava Yordanova
EBElizabeta Bachiyska
Elizabeta Bachiyska
ETElisa Tagliani
Elisa Tagliani
ABAna Baykova
Ana Baykova
YAYuliana Atanasova
Yuliana Atanasova
DCDaniela Cirillo
Daniela Cirillo
Introduction: The transmission of drug-resistant tuberculosis is one of the greatest challenges facing the global tuberculosis control. Aim: The aim of the study was to investigate the resent transmission of rifampicin resistant tuberculosis in Bulgaria and to describe the mutations related to the antimicrobials’ resistance using whole genome sequencing. Materials and methods: As part of an ECDC funded pilot study for evaluation of the systematic use of whole genome sequencing (WGS) of Mycobacterium tuberculosis (MTB) surveillance (EUSeqMyTB), Bulgaria provided 65 rifampicin resistant isolates over a three years’ timeframe (2017-2019) representing 87.5% of the notified rifampicin resistant cases. Drug resistance prediction and relatedness analysis of the resistant isolates was performed in collaboration with San Raffaele Scientific Institute, Milan, Italy. Results: Almost all of the isolates were identified as Euro-American lineage (96.9%); 18.5% of the isolates were found to be resistant to fluoroquinolones, but no mutations conferring resistance to bedaquiline or linezolid could be identified. Less than half (43.3%) of the isolates were clustered (<5 SNPs distance) into a total of seven national SNP-based clusters, while a total of six isolates were found to be part of different cross-border clusters. All clustered cases originated from Bulgaria. Conclusions: WGS has proven to be a reliable tool for surveillance and tracing of recent transmission of tuberculosis and has the potential for resistance prediction for most of the antituberculosis drugs.

31 August 2022 in Folia Medica
Verified
Journal Article
Open access
PDF file
EBElizabeta V. Bachiyska
Elizabeta V. Bachiyska
YAYuliana A. Atanasova
Yuliana A. Atanasova
ABAna I. Baykova
Ana I. Baykova
SYStanislava Yordanova
Stanislava Yordanova
Introduction: Nontuberculous mycobacteria (NTM) are representatives of the genus Mycobacterium with a worldwide distribution, associated mainly with water, soil, and biofilms. Some of NTMs, such as Mycobacterium avium complex (MAC), are etiological agents of human diseases – disseminated or with different localization, most often pulmonary. Aim: In the present study, we analyzed Mycobacterium intracellulare isolates recovered from clinical specimens of tuberculosis (TB) suspected patients in Bulgaria, 2018-2020. Materials and methods: The cultures were grown on solid and liquid media. For species identification, we used immune chromatographic (TB Ag MPT64) test and Line Probe Assay (LPA) from the positive cultures. Results: M. intracellulare was identified in 32 patients from 82,780 specimens. It was predominantly isolated in females – 62.5% vs. 37.5% in males. The most affected age group was 65 years and over (38%). The distribution of the isolates in Bulgaria was uneven. Most of them (65.6%) were concentrated in two districts of the country: Plovdiv and Sofia-city. All strains were sensitive to macrolides and aminoglycosides except one with macrolide resistance. NTM pulmonary disease was confirmed in 16 patients with M. intracellulare isolate. Conclusions: Analysing the 32 M. intracellulare isolates identified among TB suspected patients in Bulgaria between 2018 and 2020, we found that only half of them met the American Thoracic Society (ATS) diagnostic criteria for NTM pulmonary disease. For the remaining patients with M. intracellulare isolates we did not have sufficient data to support this diagnosis. Efforts by Bulgarian respiratory and microbiological societies are needed for adherence to the international guidelines.

11 July 2026 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
INIva Nenkova
Iva Nenkova
PPPetya Pavlikyanova
Petya Pavlikyanova
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
MNMihaela-Simona Naidin
Mihaela-Simona Naidin
AMAthanasios Margetis
Athanasios Margetis
MKMaria Kamusheva
Maria Kamusheva

2 May 2025 in PROBLEMS of Infectious and Parasitic Diseases
Verified
Journal Article
Open access
PDF file
SYStanislava Yordanova
Stanislava Yordanova
YAYuliana Atanasova
Yuliana Atanasova
ABAna Baykova
Ana Baykova
EBElizabeta Bachiyska
Elizabeta Bachiyska
MEMiroslav Evtimov
Miroslav Evtimov
Tuberculosis is caused by closely related mycobacterial species, designated as M.tuberculosis complex (MTBC), which includes : M.tuberculosis sensu stricto, M.africanum, M.canettii, M.bovis, M.caprae, M. microti. There is an increase in human TB cases caused by M.bovis or M.caprae in the EU. Although Bulgaria is not a bovine TB-free country, the species identification inside the MTBC is not routinely performed for human isolates and the presumably animal related pathogens could not be distinguished. This study aimed to reveal the presence of M.bovis/M.caprae as an aetiological agent on the territory of Bulgaria. For the period from 2022 to 2025, a total of 175 MTBC strains were further examined to differentiate the species. GenoType MTBC VER 1.X was used as a reliable identification tool. Almost all cases were found to be M.tuberculosis/M.canettii (n=173; 98.85%). The prevalence of Mycobacterium bovis was 0.57%. M.bovis BCG also was represented by a single isolate (0.57%). M.africanum, M.microti, or M.caprae have not been detected so far. Species identification in the MTBC is an essential step in order to limit the transmission from animal to human and to refine the treatment of the affected individuals.

10 January 2022 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
VTV. Tolchkov
V. Tolchkov
Yordan HodzhevYordan Hodzhev
Yordan Hodzhev
Borislava TsafarovaBorislava Tsafarova
Borislava Tsafarova
EBE. Bachiyska
E. Bachiyska
YAYuliana Asenova Atanasova
Yuliana Asenova Atanasova
SPStefan Panaiotov
Stefan Panaiotov
Introduction. Mycobacterium tuberculosis is the causative agent of tuberculosis. Drug susceptibility testing is performed by phenotypic and molecular tests. Commonly used for phenotypic drug susceptibility testing is the automated BACTEC system in a liquid culture medium. Drug susceptibility by line probe molecular tests was introduced almost 15 years ago. Recently whole genome sequencing (WGS) analysis of M. tuberculosis strains demonstrated that genotyping of drug-resistance could be accurately performed. Several software tools were developed.Our study aimed to perform whole-genome sequencing on phenotypically confirmed multi-drug resistant (MDR) M. tuberculosis strains, to identify drug-resistant mutations and to compare whole-genome sequencing profiles with line probe assay and phenotypic results.Materials and methods. We performed analysis on 34 MDR M. tuberculosis Bulgarian strains. Phenotypic drug susceptibility testing was performed on the BACTEC system. For molecular testing of drug susceptibility to first- and second-line tuberculostatics, we applied line probe assay Geno Type MTBDR plus v.1.0 и Geno Type MTBDR sl v.1.0. Sequencing was performed on MiSeq. Generated FASTQ files were analyzed for known drugresistant mutations with the software platform Mykrobe v.0.8.1.Results. All three methods — phenotypic analysis using the BACTEC system, genetic analysis of strains applying the Geno Type test and Mykrobe software gave comparable sensitivity/resistance results for the studied strains. All phenotypically proven rifampicin and isoniazid-resistant strains were 100% confirmed using Mykrobe software. The C-15T mutation is a marker for isoniazid resistance in strains of the SIT41 spoligotype. We observed a 75% (21/28) agreement between BACTEC and Mykrobe for ethambutol resistance. Phenotypically, 87% (n = 27) of the strains are resistant to streptomycin, but only 59% (n = 19) are proven by Mykrobe software. Comparing phenotypic and genotypic resistance to ofloxacin, amikacin and kanamycin, we observed 100% coincidence of results.Conclusions. Whole-genome sequencing approach is relatively expensive and laborious but useful for detailed analysis such as epidemiological genotyping and molecular drug susceptibility testing.